Mirati Therapeutics, Inc. (MRTX) Short Interest Update

Mirati Therapeutics, Inc. (NASDAQ:MRTX) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,693,388 shares, an increase of 48.5% from the January 12th total of 1,140,675 shares. Approximately 7.3% of the shares of the company are short sold. Based on an average daily volume of 473,771 shares, the short-interest ratio is currently 3.6 days.

In other Mirati Therapeutics news, SVP Jamie Christensen sold 10,275 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $18.00, for a total value of $184,950.00. Following the completion of the sale, the senior vice president now directly owns 12,670 shares of the company’s stock, valued at approximately $228,060. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of Mirati Therapeutics stock in a transaction on Thursday, November 16th. The stock was bought at an average cost of $13.00 per share, with a total value of $8,450,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 71,314 shares of company stock valued at $1,831,831. Insiders own 5.10% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Broadfin Capital LLC lifted its holdings in shares of Mirati Therapeutics by 19.1% during the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after acquiring an additional 400,000 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Mirati Therapeutics by 68.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock worth $3,939,000 after acquiring an additional 137,104 shares during the period. Citadel Advisors LLC bought a new position in shares of Mirati Therapeutics during the 3rd quarter worth about $268,000. Jane Street Group LLC bought a new position in shares of Mirati Therapeutics during the 3rd quarter worth about $668,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Mirati Therapeutics by 845.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after acquiring an additional 87,858 shares during the period. 66.29% of the stock is owned by institutional investors.

MRTX has been the subject of a number of research reports. Zacks Investment Research raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. HC Wainwright reissued a “buy” rating on shares of Mirati Therapeutics in a report on Tuesday, November 7th. Leerink Swann raised shares of Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $9.00 price target for the company in a report on Tuesday, November 14th. ValuEngine raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 16th. Finally, Oppenheimer reissued a “buy” rating and issued a $18.00 price target on shares of Mirati Therapeutics in a report on Wednesday, November 22nd. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $14.75.

Mirati Therapeutics (MRTX) opened at $27.10 on Friday. The company has a market cap of $723.43, a PE ratio of -8.71 and a beta of 2.10. Mirati Therapeutics has a 1-year low of $2.70 and a 1-year high of $30.50.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/11/mirati-therapeutics-inc-mrtx-short-interest-update.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply